PT2852613T - Recetores de célula t anti-ny-eso-1 murinos - Google Patents

Recetores de célula t anti-ny-eso-1 murinos

Info

Publication number
PT2852613T
PT2852613T PT13726389T PT13726389T PT2852613T PT 2852613 T PT2852613 T PT 2852613T PT 13726389 T PT13726389 T PT 13726389T PT 13726389 T PT13726389 T PT 13726389T PT 2852613 T PT2852613 T PT 2852613T
Authority
PT
Portugal
Prior art keywords
eso
cell receptors
murine anti
murine
receptors
Prior art date
Application number
PT13726389T
Other languages
English (en)
Inventor
R Parkhurst Maria
a morgan Richard
A Rosenberg Steven
Faith Rosati Shannon
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of PT2852613T publication Critical patent/PT2852613T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
PT13726389T 2012-05-22 2013-05-22 Recetores de célula t anti-ny-eso-1 murinos PT2852613T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261650020P 2012-05-22 2012-05-22

Publications (1)

Publication Number Publication Date
PT2852613T true PT2852613T (pt) 2019-05-20

Family

ID=48539439

Family Applications (2)

Application Number Title Priority Date Filing Date
PT13726389T PT2852613T (pt) 2012-05-22 2013-05-22 Recetores de célula t anti-ny-eso-1 murinos
PT191529551T PT3527584T (pt) 2012-05-22 2013-05-22 Recetores de célula t anti-ny-eso-1 murinos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT191529551T PT3527584T (pt) 2012-05-22 2013-05-22 Recetores de célula t anti-ny-eso-1 murinos

Country Status (11)

Country Link
US (3) US9487573B2 (pt)
EP (3) EP3828197A1 (pt)
JP (2) JP6378172B2 (pt)
CN (2) CN107881183B (pt)
AU (1) AU2013266421B2 (pt)
CA (1) CA2874486C (pt)
ES (2) ES2718474T3 (pt)
HK (1) HK1251874A1 (pt)
IL (1) IL235720A0 (pt)
PT (2) PT2852613T (pt)
WO (1) WO2013177247A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015113140A1 (en) 2014-01-29 2015-08-06 University Health Network Methods and compositions for producing a cell expressing a t cell receptor
AU2015339744B2 (en) 2014-10-31 2021-03-25 The Trustees Of The University Of Pennsylvania Altering gene expression in CART cells and uses thereof
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
AU2016283133A1 (en) * 2015-06-24 2018-01-04 Eureka Therapeutics, Inc. Constructs targeting NY-ESO-1 peptide/MHC complexes and uses thereof
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017076308A1 (zh) * 2015-11-04 2017-05-11 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的tcr
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
KR20190103226A (ko) 2017-01-13 2019-09-04 아게누스 인코포레이티드 Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
CN110612119A (zh) 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
US20190359678A1 (en) * 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
US10386882B2 (en) * 2017-04-14 2019-08-20 Allegro Microsystems, Llc Control circuit
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
AU2018326805B2 (en) 2017-09-01 2023-11-30 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
ES2960313T3 (es) 2017-10-05 2024-03-04 Us Health Métodos para expandir selectivamente células que expresan un TCR con una región constante murina
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
JP2021512147A (ja) 2018-01-22 2021-05-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Ｃａｒ ｔ細胞の使用方法
AU2019218785A1 (en) 2018-02-09 2020-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
WO2019162043A1 (en) * 2018-02-26 2019-08-29 Medigene Immunotherapies Gmbh Nyeso tcr
JP7342030B2 (ja) 2018-04-24 2023-09-11 アメリカ合衆国 ヒドロキシクエン酸および／またはその塩を使用してｔ細胞集団を産生する方法
CN110856751A (zh) 2018-08-24 2020-03-03 合成免疫股份有限公司 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用
CA3117539A1 (en) * 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20230258635A1 (en) 2020-09-08 2023-08-17 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
CN112375136B (zh) * 2020-11-03 2022-06-07 中国科学院微生物研究所 Ny-eso-1特异性t细胞受体筛选及其抗肿瘤用途
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CA3241588A1 (en) 2021-12-31 2023-07-06 Sri Krishna T cell therapy with vaccination as a combination immunotherapy against cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (pt) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2001519143A (ja) * 1997-10-02 2001-10-23 スノル・モレキュラー・コーポレーション 可溶性の一本鎖ｔ細胞レセプタータンパク質
CN1269412A (zh) * 2000-03-17 2000-10-11 国家人类基因组南方研究中心 一种新的人t细胞受体相关蛋白及其编码序列
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
CA2566363C (en) 2004-05-19 2014-12-16 Avidex Ltd High affinity ny-eso t cell receptor
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
PT2457928T (pt) * 2007-03-13 2017-08-17 Univ Zuerich Anticorpo monoclonal humano específico de tumores
CA2700278A1 (en) * 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modified t cell receptors and related materials and methods
CA2812153C (en) 2010-09-20 2020-06-30 Biontech Ag Antigen-specific t cell receptors and t cell epitopes

Also Published As

Publication number Publication date
IL235720A0 (en) 2015-01-29
US20180371050A1 (en) 2018-12-27
EP3828197A1 (en) 2021-06-02
JP2018196384A (ja) 2018-12-13
CN104507963B (zh) 2017-12-15
HK1251874A1 (zh) 2019-04-26
US20170029483A1 (en) 2017-02-02
US10407485B2 (en) 2019-09-10
US10087230B2 (en) 2018-10-02
EP2852613A1 (en) 2015-04-01
AU2013266421B2 (en) 2017-06-01
JP2015525208A (ja) 2015-09-03
CN104507963A (zh) 2015-04-08
CN107881183A (zh) 2018-04-06
CN107881183B (zh) 2021-04-02
EP2852613B1 (en) 2019-01-23
WO2013177247A1 (en) 2013-11-28
EP3527584B1 (en) 2020-10-14
US9487573B2 (en) 2016-11-08
CA2874486A1 (en) 2013-11-28
PT3527584T (pt) 2021-01-04
CA2874486C (en) 2021-08-24
ES2718474T3 (es) 2019-07-02
EP3527584B8 (en) 2020-12-16
AU2013266421A1 (en) 2014-12-04
EP3527584A1 (en) 2019-08-21
JP6378172B2 (ja) 2018-08-22
US20150141347A1 (en) 2015-05-21
ES2835200T3 (es) 2021-06-22

Similar Documents

Publication Publication Date Title
HK1251874A1 (zh) 鼠抗-ny-eso-1 t細胞受體
HK1222338A1 (zh) 細胞受體
HK1211039A1 (en) Engineering -cell receptors
HK1211623A1 (en) Cell lines
IL235355B (en) A method for creating receptors for t cells
HK1221724A1 (zh) 細胞受體
ZA201300621B (en) T cell receptors
EP2919313A4 (en) SOLID ELECTROLYTE
EP2876715A4 (en) FUEL CELL
EP2911230A4 (en) CELL
EP2698839A4 (en) BLOCK OF CELLS
EP2707886A4 (en) ELECTROLYTE
EP2831949A4 (en) SODIUM OXYGEN CELLS
EP2899786A4 (en) FUEL CELL
HK1199148A1 (en) Electrochemical cell
IL239484A0 (en) Materials for omitting enterprise-tumor cells
EP2919308A4 (en) Polyelectrolyte FUEL CELL
EP2830138A4 (en) BIO FUEL CELL
EP2835852A4 (en) FUEL CELL
EP2830130A4 (en) FUEL CELL
GB201322430D0 (en) T cell receptors
EP2863459A4 (en) FLAT CELL
GB201220017D0 (en) Fuel cell components
EP2882020A4 (en) FUEL CELL
GB2500031B (en) Fuel cells